key: cord-0279843-fel74nix authors: Sadoff, J.; Le Gars, M.; Cardenas, V.; Shukarev, G.; Vaissiere, N.; Heerwegh, D.; Truyers, C.; de Groot, A. M.; Scheper, G.; Hendriks, J.; Ruiz-Guinazu, J.; Struyf, F.; Van Hoof, J.; Douoguih, M.; Schuitemaker, H. title: Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting date: 2021-08-26 journal: nan DOI: 10.1101/2021.08.25.21262569 sha: d93050cdda386f9444be512809b8595538ed7c68 doc_id: 279843 cord_uid: fel74nix Background: We evaluated the durability of SARS-CoV-2 antibody levels elicited by the single dose Janssen COVID-19 vaccine, Ad26.COV2.S, and the impact on antibody responses of boosting with Ad26.COV2.S after 6 months in clinical trial participants. Methods: Spike-binding antibody and SARS-CoV-2 neutralizing antibody levels elicited by a single-dose Ad26.COV2.S (5x1010 viral particles [vp]) primary regimen and booster doses (5x1010 vp and 1.25x1010 vp) were assessed by ELISA and wild-type VNA in sera from participants in a Phase 1/2a clinical trial (Cohort 1a, 18-55 years old, N=25; Cohort 2a, 18-55 years old boosted at 6 months, N=17; Cohort 3, [≥]65 years old, N=22) and a Phase 2 clinical trial (18-55 and [≥]65-year old participants boosted at 6 months, total N=73). Neutralizing antibody levels were determined approximately 8 months after the primary vaccination in participants aged 18-55 years and approximately 9 months in participants aged [≥]65 years. Binding antibody levels were evaluated 6 months after primary vaccination and 7- and 28-days after booster doses in both age groups. Results: A single dose of Ad26.COV2.S elicited neutralizing antibodies that remained largely stable for approximately 8-9 months and binding antibodies that remained stable for at least 6 months irrespective of age group. A 5x1010 vp booster dose at 6 months post prime vaccination in 18-55-year-old adults elicited a steep and robust 9-fold increase at Day 7 post boost compared to Day 29 levels following the initial immunization. A lower booster dose of 1.25x1010 vp at 6 months in adults 18-55 and [≥]65 years of age also elicited a rapid and high increase of 6-7.7 fold at Day 28 post boost compared to Day 29 levels following the initial immunization, with similar magnitude of post-boost responses in both age groups. Conclusions: A single dose of Ad26.COV2.S, which demonstrated protection in a Phase 3 efficacy trial, elicited durable neutralizing and binding antibodies for at least 8 and 6 months, respectively, in adults >18 years of age at levels similar to Day 29 responses. A 5x1010 vp or 1.25x1010 vp booster dose at 6 months elicited rapid and robust increases in spike binding antibody levels. The anamnestic responses after booster immunization imply robust immune memory elicited by single-dose Ad26.COV2.S. 3 at Day 28 post boost compared to Day 29 levels following the initial immunization, with similar magnitude of post-boost responses in both age groups. Conclusions: A single dose of Ad26.COV2.S, which demonstrated protection in a Phase 3 efficacy trial, elicited durable neutralizing and binding antibodies for at least 8 and 6 months, respectively, in adults >18 years of age at levels similar to Day 29 responses. A 5x10 10 vp or 1.25x10 10 vp booster dose at 6 months elicited rapid and robust increases in spike binding antibody levels. The anamnestic responses after booster immunization imply robust immune memory elicited by single-dose Ad26.COV2.S. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic. Janssen's COVID-19 vaccine, Ad26.COV2.S, 1 has been demonstrated to be safe, immunogenic, and to confer high protective efficacy against severe-critical COVID-19 disease and COVID-19-related hospitalization and death. 2, 3 However, as already observed for one of the other COVID-19 vaccines, 4-6 vaccine-mediated protection against COVID-19 may decline with time. This decline may imply that antibody levels are waning or are less effective against emerging variants of concern, that immune priming has elicited insufficient immune memory to support anamnestic responses upon exposure to SARS-CoV-2, or a combination of these. Longitudinal evaluation of immune responses following primary vaccination gives insight into the durability of SARS-CoV-2-specific immunity and the potential need for a booster dose to further increase antibody titers at or above protective levels and to enhance immune memory. High antibody (Ab) titers are even more important in the context of emerging variants of concern that are relatively resistant to antibody mediated neutralization 7-9 and for which antibody levels may need to be higher to confer protection against acquisition and mild-to-moderate disease, especially in populations at high risk for COVID-19, such as the elderly population. Here, in Phase 1/2a and Phase 2 clinical trial participants 18-55 and ≥65 years of age, we evaluated the durability of SARS-CoV-2 neutralizing antibody and binding antibody levels elicited by a single dose of Ad26.COV2.S at 5x10 10 vp as a primary vaccination. Moreover, we studied the impact of homologous boosting with Ad26.COV2.S at a 5x10 10 vp dose 6-months post primary vaccination on these antibody levels. In addition, we tested the impact of a 4-fold lower booster dose of Ad26.COV2.S at 6 months post primary vaccination to assess the robustness of immune memory elicited by the single dose primary regimen, both in younger and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint older adults. Overall, Ad26.COV2.S-elicited immunity is durable for at least 8 months and can be further increased with a booster in adults >18 years of age. Spike-binding and neutralizing antibody levels were assessed by ELISA during a 6-to 9-month follow up after a single dose Ad26.COV2.S primary regimen, and after a booster dose at 6 months post primary regimen. Neutralizing antibody titers were evaluated in a subset of participants from Phase 1/2a Cohorts 1a and 3 and Phase 2. Binding antibody geometric mean concentrations (GMCs) and neutralizing antibody geometric mean titers (GMTs) were determined per study protocols and amendments at various days based on regimen and age group after primary vaccination, as shown in Figures 1-3 . Binding antibody GMCs were uniformly evaluated at days 7 and 28 after booster doses. A participant was considered a responder after primary vaccination regimen if: baseline antibody titers were below the lower limit of quantification (LLOQ) prior vaccination and were above the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint LLOQ after vaccination; or if baseline antibody titers were above LLOQ prior to vaccination and were 4-fold higher than baseline titers after vaccination. All participants were monitored for solicited and unsolicited local and systemic adverse events (AEs) by 7-day diary cards and 28-day follow-up for unsolicited AEs. Serious adverse events (SAEs) and AEs of special interest were collected throughout each study. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint Neutralizing antibodies capable of inhibiting wild-type virus infections were quantified using the wild-type virus microneutralization assay (MNA) that was developed and qualified by Public Health England (PHE). The virus stocks used were derived from the Victoria/1/2020 strain, and the LLOQ of the assay is 58 IC50. In brief, 6 two-fold serial dilutions of heat-inactivated human serum samples were prepared in 96-well transfer plate(s). The SARS-CoV-2 wild-type virus was subsequently added to the serum dilutions at a target working concentration (approximately 100 plaque-forming units [PFU]/well) and incubated at 37°C for 60 to 90 minutes. The serum-virus mixture was then transferred onto assay plates previously seeded overnight with Vero E6 African green monkey kidney cells and incubated at 37°C and 5% CO2 for 60 to 90 minutes before the addition of carboxymethyl cellulose (CMC) overlay medium and further incubation for 24 hours. Cells were then fixed and stained using an antibody pair specific for the SARS-CoV-2 RBD spike (S) protein, and immunoplaques were visualized using TrueBlue TM substrate (KPL, Milford, MA, USA). Immunoplaques were counted using the Immunospot Analyzer (Cellular Technology Limited, Cleveland, OH, USA). The immunoplaque counts were exported to SoftMax Pro (Molecular Devices, San Jose, CA, USA) and the neutralizing titer of a serum sample was calculated as the reciprocal serum dilution corresponding to the 50% neutralization antibody titer (IC50) for that sample. SARS-CoV-2 pre-spike-specific binding antibody concentrations were determined using the human SARS-CoV-2 pre-spike IgG ELISA, an indirect ELISA that is based on antibody/antigen . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint interactions. The SARS-CoV-2 antigen was a stabilized pre-fusion spike protein ([2P] , Δfurin, T4 foldon, His-tag), derived from the first clinical isolate of the Wuhan strain (Wuhan, 2019, whole genome sequence NC_045512), produced in ES-293 cells. The ELISA was developed and qualified for human serum at Nexelis, (Laval, PQ, Canada). The lower limit of quantification of the assay is 53 ELISA Units (EU/mL). In brief, purified SARS-CoV-2 pre-spike antigen was adsorbed to the wells of a microplate and diluted serum samples (test samples, standard, and quality controls) were added. Unbound sample was washed away, and enzyme-conjugated anti-human IgG added. After washing excess conjugate away, 3,3′,5,5′-tetramethylbenzidine (TMB) colorimetric substrate was added. After the established time period, the reaction was stopped. A reference standard on each test plate was used to quantify the amount of antibodies against SARS-CoV-2 pre-spike in the sample according to the unit assigned by the standard (EU/mL). We previously reported the short-term immunogenicity after single-dose primary vaccination with Ad26.COV2.S in participants of our Phase 1/2a study. 2 Here we report the levels of and post-booster reactogenicity appeared similar as compared to the previously reported Cohort 1 reactogenicity. 2 Reactogenicity following the boost may have been more comparable to the reactogenicity previously reported from Cohort 1 following a second dose at 57 days after the initial dose, which was lower than following the initial priming dose, but the limited number of participants precludes precision in these measurements. In the Phase 2 study (COV2001), when booster doses of 1.25x10 10 vp Ad26.COV2.S were given at 6 months after the primary single-dose immunization of 5x10 10 vp in 81 participants, solicited AEs after the primary dose versus after the booster were 67.9% versus 54%, respectively, and for grade 3 solicited AEs, 1.2% versus 0%, for solicited local AEs, 51.9% versus 47%, for solicited . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint local AEs of grade 3 or more 0% versus 0%, for solicited systemic AEs, 66.7% versus 28%, and for solicited systemic AEs of grade 3 or more, 1.2% vs 0%. We recently reported that a single dose of the Janssen Ad26.COV2.S COVID-19 vaccine is immunogenic and highly efficacious against severe COVID-19 disease and COVID-19 related hospitalization and death, also in areas where the beta variant of concern had high prevalence. 2, 3 In addition, data from the Sisonke study in South Africa among 480,000 health care workers, 10 which was performed in the context of the current surge with the Delta variant, demonstrates high efficacy of single-dose Ad26.COV2.S against COVID-19 related hospitalization and death due to the Delta variant. Here, in participants of our Phase 1/2a study, we observed that following a single dose of Ad26.COV2.S (5x10 10 vp), neutralizing and binding antibody levels remained at or above postprime levels in the majority of participants, irrespective of age. In the younger age group, antibody levels at 6 months were similar to levels on Day 29 while in older adults the antibody levels showed a slight and insignificant decline between Day 29 and month 6 post vaccination. These durable antibody levels are consistent with our previous observation in a sub-cohort of our Phase 1/2a study where we also demonstrated stable humoral immune responses for 8 months after primary vaccination with Ad26.COV2.S in 18-55 year-old adults, including against Beta and Delta variants of concern. 7 Together, these data imply that a single dose of Ad26.COV2.S at a dose level of 5x10 10 vp elicits a high quality and durable immune response of at least 6 to 8 months in adults >18 years of age. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint A mechanistic immune correlate of protection has not yet been defined but antibody levels do seem to have some correlation with vaccine efficacy. [11] [12] [13] In our ENSEMBLE Phase 3 efficacy trial, high vaccine efficacy against severe/critical COVID-19 disease was observed as early as Day 7 after vaccination, and by Day 14 after vaccination for prevention of hospitalization and death. GMT of antibodies at 6 to 8 months following immunization were similar, or slightly lower in participants ≥65 years old, to GMTs at 28 days after immunization at a time when protection was seen in our efficacy study, which is similar to results reported earlier in a subcohort or our Phase 1/2a study. 7 It is therefore expected that these durable immune responses may translate into durable vaccine efficacy. Waning vaccine elicited immune responses and the emergence of virus variants may impact vaccine efficacy. 8, 9 While immune responses were preserved in the majority of participants, we did observe that few participants in both age groups had undetectable levels of SARS-CoV-2 specific neutralizing antibodies at 6 months post primary vaccination with Ad26.COV2.S. Similar or even higher numbers of participants with declining neutralizing antibodies to undetectable levels have been reported for recipients of mRNA based COVID-19 vaccines. 14, 15 We explored here the potential utility of a booster immunization following initial vaccination with Ad26.COV2.S and show that a homologous booster with Ad26.COV2.S (5x10 10 vp) at 6 months after primary vaccination leads to a rapid increase in spike specific antibody levels. In 18-55 year-old adults, booster doses of either 5x10 10 vp or 1.25x10 10 vp gave rapid and strong increases in antibody levels that were significantly higher than antibody levels at Day 29 after primary vaccination, the period in which in our phase 3 efficacy study protection from hospitalization and death by our vaccine was demonstrated, with protection against severe disease commencing already at day 7, at lower levels of antibody than seen at Day 28. 16 In . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint addition, it is important to emphasize that even older adults in whom spike specific antibody titers had declined to undetectable levels at month 6 post primary vaccination showed similar strong responses to this low dose booster vaccination. These anamnestic responses even in individuals with undetectable antibodies may also occur in response to SARS-CoV-2 infection and hence these people are likely still protected against severe COVID-19. At this point, only ELISA data were available from samples obtained post booster vaccination and VNA data will become available soon. However, from our previous analyses we know that Ad26.COV2.S-elicited spike specific binding levels strongly correlate with levels of SARS-COV-2 neutralizing antibodies. 2 These data also confirm our earlier observations 2,17,18 that homologous boosting with an Ad26based vaccine works very well, regardless of the induction of antibodies against the vector. Ad26 antibody titers after vaccination are relatively low and can apparently be overcome by even a low dose level of a booster vaccination. It was recently reported that Ad26.COV2.S is also capable of boosting immune responses in people who had received a mRNA based COVID-19 vaccine for primary vaccination. 19 This data set suggests that Ad26.COV2.S may be utilized to boost both mRNA and Ad26.COV2.S vaccinated individuals. Additional clinical studies are ongoing to confirm the potential of both homologous and heterologous booster strategies with Ad26.COV2.S. The 9-fold increase in binding antibody levels, observed at Day 7 after boosting at 6 months with the 5x10 10 vp dose level was greater than the 2.2-fold increase at Day 15 after a second dose at 2 months after the first vaccination. 2 The benefit of a longer interval between vaccine doses on the magnitude of immune responses has been reported previously 20 and implies that a booster dose at 6-8 months or perhaps even later timepoints may be optimal. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint In the previously reported Phase 1/2a study, 2 solicited and unsolicited local and systemic adverse events were found to be transient and generally mild following a 5x10 10 vp dose given 2 months after the single priming dose with less severity compared to the initial dose. Boosting at 6 months with either 5x10 10 vp dose or the 1.25x10 10 vp dose in a similar way were found to be safe and well tolerated with primarily transient mild systemic and local adverse events. In the current study, while the numbers of participants given the 5x10 10 vp booster (N=17) was too small to precisely measure the difference between local and systemic AEs following primary immunization versus booster, the number boosted with the 1.25x10 10 vp dose (N=81) provided the opportunity to compare this difference in a more robust manner. Solicited local and systemic AEs of grade 3 or more were extremely low following primary or booster immunization, with none seen following the booster. Solicited local AEs were similar after the primary vaccination versus the booster (51% vs 47%) despite the difference in dose, while solicited systemic AEs were demonstrably lower after the boost (61.7% vs 28%). This difference may be attributed to the reduction in reactogenicity seen with Ad26.COV2.S as noted above following a second dose and possibly due to the lower dose, although the lower dose had no effect on local reactogenicity. While our current study is much too small to estimate the risk of a booster dose for the very rare thrombosis with thrombocytopenia syndrome (TTS), 21, 22 data obtained with the AstraZeneca vaccine demonstrate that the risk for TTS after a second dose of ChAdOx1 nCoV-19 vaccine is even significantly lower, 23 an observation that can likely be extended to Ad26.COV2.S. Overall, our data demonstrate that a single dose of Ad26.COV2.S elicits durable protective immunity for at least 8 months as well as immune memory that allows for robust anamnestic responses following booster vaccination. Boosting leads to rapid increases of humoral immune . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. HHSO100201700018C. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint A . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262569 doi: medRxiv preprint Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses Interim results of a phase 1-2a trial of S COVID-19 vaccine Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network New COVID-19 Cases and mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants Sisonke Update on the Janssen®(JNJ) Ad26.COV2.S vaccine Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Evidence for antibody as a protective correlate for COVID-19 vaccines Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants Durability of responses after SARS-CoV-2 mRNA-1273 vaccination Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity A double-blind, randomized, placebocontrolled phase 1 study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus vaccine A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination Safety Monitoring of the Janssen